RAPP Rapport Therapeutics, Inc.

NASDAQ
$47.42

Rapport Therapeutics, Inc. (RAPP) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $1.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +14.5% since its last earnings release on August 5, 2026.

Rapport Therapeutics Missed Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($1.21)
Rev est $20M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $46.81

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Rapport Therapeutics, Inc.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Sector

Healthcare

Industry

Biotechnology